Journal of the National Cancer Center最新文献

英文中文

Artificial intelligence-integrated wearable biomedical devices for cancer management 用于癌症管理的人工智能集成可穿戴生物医学设备

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.09.001

Penghua Zhai , Weixin Xu , Guifang Duan , Yukun Wu , Mingxin Qi , Lingqian Chang , Wei Mu

Cancer remains the leading cause of death globally. Early diagnosis and intervention play deterministic roles in improving clinical prognosis. Traditional cancer management heavily depends on central hospital-based imaging and invasive diagnostics, which are intermittent and costly. Moreover, these strategies show limitations to patient compliance and real-time diagnosis. The emergence of wearable biomedical devices (WBDs) has offered a compelling alternative, enabling continuous, non-invasive in situ monitoring of bio-signals and real-time tissue imaging in daily settings. In particular, these devices have recently been integrated with therapeutic modules and artificial intelligence (AI) and have been adapted to closed-loop interventions, allowing for precise, on-demand drug delivery and localized therapy. In this review, we provide an overview of AI-integrated WBDs with their applications in cancer screening, diagnosis, and therapy. To solve the remaining issues of inaccurate screening, delayed intervention and severe side effects, the innovation of WBDs mainly includes conformable wearing structures, adhesive materials and integrated sensors/drug delivery modules. The integration of AI into WBDs has demonstrated high performance in improving signal-to-noise ratio (SNR) and real-time data processing, which significantly enhance the capabilities in long-term monitoring, and patient-specific bio-signal variations. The last session provides future directions for AI-integrated WBDs, focusing on improving SNR, reducing false positives caused by high sensitivity, and addressing patient data privacy concerns during AI training.

癌症仍然是全球死亡的主要原因。早期诊断和干预对改善临床预后起决定性作用。传统的癌症管理严重依赖于以医院为基础的中心成像和侵入性诊断，这些诊断是断断续续且昂贵的。此外，这些策略在患者依从性和实时诊断方面存在局限性。可穿戴生物医学设备（wbd）的出现提供了一种引人注目的替代方案，可以在日常环境中对生物信号进行连续、无创的原位监测和实时组织成像。特别是，这些设备最近已与治疗模块和人工智能（AI）集成，并已适应闭环干预，允许精确，按需给药和局部治疗。本文就人工智能集成wbd及其在癌症筛查、诊断和治疗中的应用进行综述。针对目前存在的筛选不准确、干预延迟、副作用严重等问题，wbd的创新主要包括可穿戴结构、黏附材料和集成传感器/给药模块。将人工智能集成到wbd中，在提高信噪比（SNR）和实时数据处理方面表现出色，从而显著增强了长期监测和患者特异性生物信号变化的能力。最后一节提供了人工智能集成wbd的未来发展方向，重点是提高信噪比，减少高灵敏度导致的误报，以及解决人工智能训练期间患者数据隐私问题。

{"title":"Artificial intelligence-integrated wearable biomedical devices for cancer management","authors":"Penghua Zhai , Weixin Xu , Guifang Duan , Yukun Wu , Mingxin Qi , Lingqian Chang , Wei Mu","doi":"10.1016/j.jncc.2025.09.001","DOIUrl":"10.1016/j.jncc.2025.09.001","url":null,"abstract":"<div><div>Cancer remains the leading cause of death globally. Early diagnosis and intervention play deterministic roles in improving clinical prognosis. Traditional cancer management heavily depends on central hospital-based imaging and invasive diagnostics, which are intermittent and costly. Moreover, these strategies show limitations to patient compliance and real-time diagnosis. The emergence of wearable biomedical devices (WBDs) has offered a compelling alternative, enabling continuous, non-invasive <em>in situ</em> monitoring of bio-signals and real-time tissue imaging in daily settings. In particular, these devices have recently been integrated with therapeutic modules and artificial intelligence (AI) and have been adapted to closed-loop interventions, allowing for precise, on-demand drug delivery and localized therapy. In this review, we provide an overview of AI-integrated WBDs with their applications in cancer screening, diagnosis, and therapy. To solve the remaining issues of inaccurate screening, delayed intervention and severe side effects, the innovation of WBDs mainly includes conformable wearing structures, adhesive materials and integrated sensors/drug delivery modules. The integration of AI into WBDs has demonstrated high performance in improving signal-to-noise ratio (SNR) and real-time data processing, which significantly enhance the capabilities in long-term monitoring, and patient-specific bio-signal variations. The last session provides future directions for AI-integrated WBDs, focusing on improving SNR, reducing false positives caused by high sensitivity, and addressing patient data privacy concerns during AI training.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 6","pages":"Pages 561-576"},"PeriodicalIF":9.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer? A 9-year cohort study of 9.08 million adults in China 男性乳腺癌的疾病负担和保健利用是否存在种族差异？一项对中国908万成年人进行的为期9年的队列研究

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.05.006

Jieying Chen , Liying Qiao , Ying Yan , Meng Qi , Yunjing Zhang , Weiwei Kang , Huziwei Zhou , Yuelin Yu , Yalei Ke , Yuling Jiang , Yingting Rao , Lu Xu , Guohua He , Jing Ren , Xue Yan , Siwei Deng , Xinyu Yang , Yutong Song , Yingzi Yang , Qiaorui Wen , Shengfeng Wang

Background

As a rare disease, male breast cancer (MBC) is of increasing concern in China. Whether health inequalities of disease burden and healthcare utilization exist by ethnicity in male breast cancer remains unclear. We aim to measure disease burden and healthcare utilization by ethnicity among male breast cancer patients in China.

Methods

A retrospective cohort study was established during 2012–2021 based on the Inner Mongolia Regional Health Information Platform. Disease burden, including incidence, 5-year prevalence, mortality, survival rate, and medical cost were analyzed.

Results

Among 630 participants (mean [SD] age, 59.4 [13.1] years), age-standardized rates of incidence were 1.2 (95% CI: 0.4–2.1) per 100, 000. All-cause mortality was 50.8 per 1000 person-years (95% CI: 42.4–60.4). Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], P=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality. Meanwhile, few significant disparities in healthcare utilization between Han and Mongolian were observed.

Conclusions

This study revealed a moderate disease burden and relatively lower healthcare utilization for male breast cancer in Inner Mongolia, China. No significant ethnic disparities existed in disease burden and healthcare utilization. However, increased attention to male breast cancer is warranted due to the crucial influence of economic factors on potential ethnic disparities.

背景男性乳腺癌（MBC）作为一种罕见疾病，在中国越来越受到关注。男性乳腺癌的疾病负担和医疗保健利用是否存在种族不平等尚不清楚。我们的目的是衡量中国男性乳腺癌患者的疾病负担和医疗保健利用。方法基于内蒙古区域卫生信息平台，建立2012-2021年的回顾性队列研究。分析疾病负担，包括发病率、5年患病率、死亡率、生存率和医疗费用。结果在630名参与者中（平均[SD]年龄59.4[13.1]岁），年龄标准化发病率为每10万人1.2例（95% CI: 0.4-2.1）。全因死亡率为50.8 / 1000人年（95% CI: 42.4-60.4）。就种族而言，蒙古人的5年年龄标准化患病率高于汉族（3.2[95% CI: 2.5-4.0] vs 2.3[95% CI: 1.7-3.0]， P=0.016），但在发病率、生存率、全因死亡率和乳腺癌特异性死亡率风险方面没有显著差异。同时，汉蒙两族在医疗保健利用方面没有明显差异。结论内蒙古地区男性乳腺癌患者疾病负担较轻，医疗保健利用率较低。在疾病负担和医疗保健利用方面不存在显著的种族差异。然而，由于经济因素对潜在的种族差异具有关键影响，因此有必要增加对男性乳腺癌的关注。

{"title":"Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer? A 9-year cohort study of 9.08 million adults in China","authors":"Jieying Chen , Liying Qiao , Ying Yan , Meng Qi , Yunjing Zhang , Weiwei Kang , Huziwei Zhou , Yuelin Yu , Yalei Ke , Yuling Jiang , Yingting Rao , Lu Xu , Guohua He , Jing Ren , Xue Yan , Siwei Deng , Xinyu Yang , Yutong Song , Yingzi Yang , Qiaorui Wen , Shengfeng Wang","doi":"10.1016/j.jncc.2025.05.006","DOIUrl":"10.1016/j.jncc.2025.05.006","url":null,"abstract":"<div><h3>Background</h3><div>As a rare disease, male breast cancer (MBC) is of increasing concern in China. Whether health inequalities of disease burden and healthcare utilization exist by ethnicity in male breast cancer remains unclear. We aim to measure disease burden and healthcare utilization by ethnicity among male breast cancer patients in China.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was established during 2012–2021 based on the Inner Mongolia Regional Health Information Platform. Disease burden, including incidence, 5-year prevalence, mortality, survival rate, and medical cost were analyzed.</div></div><div><h3>Results</h3><div>Among 630 participants (mean [SD] age, 59.4 [13.1] years), age-standardized rates of incidence were 1.2 (95% CI: 0.4–2.1) per 100, 000. All-cause mortality was 50.8 per 1000 person-years (95% CI: 42.4–60.4). Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5–4.0] vs 2.3[95% CI: 1.7–3.0], <em>P</em>=0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality. Meanwhile, few significant disparities in healthcare utilization between Han and Mongolian were observed.</div></div><div><h3>Conclusions</h3><div>This study revealed a moderate disease burden and relatively lower healthcare utilization for male breast cancer in Inner Mongolia, China. No significant ethnic disparities existed in disease burden and healthcare utilization. However, increased attention to male breast cancer is warranted due to the crucial influence of economic factors on potential ethnic disparities.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 6","pages":"Pages 577-585"},"PeriodicalIF":9.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reframing the ozone–lung cancer link: toward exposure equity in urban China 重新构建臭氧与肺癌的联系：中国城市暴露的公平性

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.07.002

Man Sun , Dan Zang , Jun Chen

引用次数: 0

Breaking the noninflamed barrier: tumor-secreted erythropoietin as a master regulator of immunosuppressive macrophages 打破非炎症屏障：肿瘤分泌的促红细胞生成素作为免疫抑制巨噬细胞的主要调节因子

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.09.004

Xudong Wang , Yaqi Tao , Jianhong Zhou , Jie Zhang , Guoqing Ding

引用次数: 0

Restoring dendritic cell interstitial motility via PDE5 inhibition for sustained antitumor immunity 通过抑制PDE5恢复树突状细胞间质运动，实现持续的抗肿瘤免疫

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.09.005

Ruichen Zang , Chen Zhang , Guoqing Ding , Jie Zhang

引用次数: 0

Ten-year evaluation of HPV vaccine influence on non-vaccine-type-related cervical infections and precancers in Chinese females: follow-up from a randomized control trial HPV疫苗对中国女性非疫苗型相关宫颈感染和癌前病变影响的十年评价：一项随机对照试验的随访

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.07.003

Tianmeng Wen , Changchang Dun , Shangying Hu , Qinjing Pan , Xun Zhang , Fanghui Zhao

Objective

The long-term influence of human papillomavirus (HPV) vaccination on untargeted types is poorly understood. The study assessed the influence of AS04-HPV-16/18 vaccination on non-vaccine-type infections and precancers through post-hoc analyses of a 10-year follow-up of China’s first HPV vaccine trial.

Methods

In the clinical trial, females aged 18–25 years (N = 6051) were randomized 1:1 to receive either three doses of AS04-HPV-16/18 vaccine or control and followed for 6 years. After this trial, all participants were invited to an extended 10-year follow-up. The present post-hoc analyses evaluated cross-protection and type replacement based on virological and pathological endpoints.

Results

The AS04-HPV-16/18 vaccine provided 43.15 % (95 % CI: 20.17 %–59.96 %) cross-protection against 6-month persistent infections related to HPV-31/33/45, while cross-protection against other non-vaccine types (HPV-35/39/51/52/56/58/59/66/68) was non-significant. Notably, an increase in non-vaccine-preventable-type-related cervical intraepithelial neoplasia of grade 2 (CIN2) or worse was noted in the vaccine group (attributable proportion: 48.40 %), compared to 29.52 % in the control group (P = 0.020). No significant differences in incidence or prevalence of non-vaccine-preventable-type infections were found between groups.

Conclusions

A significant increase in precancers caused by the non-vaccine-preventable types was demonstrated, despite no evidence of viral replacement 10 years post-vaccination.

目的人乳头瘤病毒（HPV）疫苗接种对非靶向型的长期影响尚不清楚。该研究通过对中国首个HPV疫苗试验的10年随访分析，评估了AS04-HPV-16/18疫苗接种对非疫苗型感染和癌前病变的影响。方法在临床试验中，年龄在18-25岁的女性（N = 6051）按1:1的比例随机分为三剂AS04-HPV-16/18疫苗和对照组，随访6年。试验结束后，所有参与者都被邀请进行为期10年的随访。目前的事后分析评估了基于病毒学和病理终点的交叉保护和类型替代。结果AS04-HPV-16/18疫苗对HPV-31/33/45相关6个月持续性感染的交叉保护作用为43.15% (95% CI: 20.17% ~ 59.96%)，而对其他非疫苗类型（HPV-35/39/51/52/56/58/59/66/68）的交叉保护作用不显著。值得注意的是，在疫苗组中，非疫苗可预防型相关的2级（CIN2）或更严重的宫颈上皮内瘤变增加（归因比例：48.40%），而对照组为29.52% （P = 0.020）。两组间非疫苗可预防型感染的发生率或流行率无显著差异。结论非疫苗可预防型引起的癌前病变显著增加，尽管未发现疫苗接种后10年病毒替代的证据。

{"title":"Ten-year evaluation of HPV vaccine influence on non-vaccine-type-related cervical infections and precancers in Chinese females: follow-up from a randomized control trial","authors":"Tianmeng Wen , Changchang Dun , Shangying Hu , Qinjing Pan , Xun Zhang , Fanghui Zhao","doi":"10.1016/j.jncc.2025.07.003","DOIUrl":"10.1016/j.jncc.2025.07.003","url":null,"abstract":"<div><h3>Objective</h3><div>The long-term influence of human papillomavirus (HPV) vaccination on untargeted types is poorly understood. The study assessed the influence of AS04-HPV-16/18 vaccination on non-vaccine-type infections and precancers through post-hoc analyses of a 10-year follow-up of China’s first HPV vaccine trial.</div></div><div><h3>Methods</h3><div>In the clinical trial, females aged 18–25 years (<em>N</em> = 6051) were randomized 1:1 to receive either three doses of AS04-HPV-16/18 vaccine or control and followed for 6 years. After this trial, all participants were invited to an extended 10-year follow-up. The present post-hoc analyses evaluated cross-protection and type replacement based on virological and pathological endpoints.</div></div><div><h3>Results</h3><div>The AS04-HPV-16/18 vaccine provided 43.15 % (95 % CI: 20.17 %–59.96 %) cross-protection against 6-month persistent infections related to HPV-31/33/45, while cross-protection against other non-vaccine types (HPV-35/39/51/52/56/58/59/66/68) was non-significant. Notably, an increase in non-vaccine-preventable-type-related cervical intraepithelial neoplasia of grade 2 (CIN2) or worse was noted in the vaccine group (attributable proportion: 48.40 %), compared to 29.52 % in the control group (<em>P</em> = 0.020). No significant differences in incidence or prevalence of non-vaccine-preventable-type infections were found between groups.</div></div><div><h3>Conclusions</h3><div>A significant increase in precancers caused by the non-vaccine-preventable types was demonstrated, despite no evidence of viral replacement 10 years post-vaccination.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 6","pages":"Pages 586-592"},"PeriodicalIF":9.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneity sonata: Orchestrating distal metastasis under stress 异质性奏鸣曲：压力下远端转移的协调

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.09.003

Baiyang Liu , Yongbin Chen

引用次数: 0

Conditional relative survival: an essential tool for risk stratification of (breast) cancer patients 条件相对生存：乳腺癌患者风险分层的重要工具

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.08.001

Luigino Dal Maso , Annalisa Trama , Fabiola Giudici , Stefano Guzzinati

引用次数: 0

Reply: reframing the ozone–lung cancer link: toward exposure equity in urban China 回复：重新构建臭氧与肺癌的联系：中国城市暴露的公平性

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.10.001

Yi Wu , Chunqi Wang , Chunxiao Xu , Siming Wang , Rongshou Zheng , Chunying Lin , Xiaoyan Zhang , Bowang Chen , Yang Yang , Wei Li , Guangda He , Jianlan Cui , Wei Xu , Lijuan Song , Hao Yang , Wenyan He , Yan Zhang , Jing Wei , Tiantian Li , Xi Li

引用次数: 0

Corrigendum to Deep learning model based on primary tumor to predict lymph node status in clinical stage IA lung adenocarcinoma: a multicenter study [Journal of the National Cancer Center 4 (2024) 233–240] 基于原发肿瘤预测临床IA期肺腺癌淋巴结状态的深度学习模型的勘误表：一项多中心研究[Journal of the National Cancer Center 4 (2024) 233-240]

IF 9.4 Q1 ONCOLOGY

Journal of the National Cancer Center

Pub Date : 2025-12-01 DOI: 10.1016/j.jncc.2025.08.002

Li Zhang , Hailin Li , Shaohong Zhao , Xuemin Tao , Meng Li , Shouxin Yang , Lina Zhou , Mengwen Liu , Xue Zhang , Di Dong , Jie Tian , Ning Wu

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the National Cancer Center

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀